492 related articles for article (PubMed ID: 25316657)
1. FAK signaling in human cancer as a target for therapeutics.
Lee BY; Timpson P; Horvath LG; Daly RJ
Pharmacol Ther; 2015 Feb; 146():132-49. PubMed ID: 25316657
[TBL] [Abstract][Full Text] [Related]
2. Focal adhesion kinase: a potential target in cancer therapy.
van Nimwegen MJ; van de Water B
Biochem Pharmacol; 2007 Mar; 73(5):597-609. PubMed ID: 16997283
[TBL] [Abstract][Full Text] [Related]
3. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.
Shanthi E; Krishna MH; Arunesh GM; Venkateswara Reddy K; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Oct; 24(10):1077-100. PubMed ID: 25113248
[TBL] [Abstract][Full Text] [Related]
4. Targeting focal adhesion kinase signaling in tumor growth and metastasis.
Schwock J; Dhani N; Hedley DW
Expert Opin Ther Targets; 2010 Jan; 14(1):77-94. PubMed ID: 20001212
[TBL] [Abstract][Full Text] [Related]
5. Signal transduction by focal adhesion kinase in cancer.
Zhao J; Guan JL
Cancer Metastasis Rev; 2009 Jun; 28(1-2):35-49. PubMed ID: 19169797
[TBL] [Abstract][Full Text] [Related]
6. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
[TBL] [Abstract][Full Text] [Related]
7. FAK expression regulation and therapeutic potential.
Li S; Hua ZC
Adv Cancer Res; 2008; 101():45-61. PubMed ID: 19055942
[TBL] [Abstract][Full Text] [Related]
8. Focal adhesion kinase as a cancer therapy target.
Golubovskaya VM
Anticancer Agents Med Chem; 2010 Dec; 10(10):735-41. PubMed ID: 21214510
[TBL] [Abstract][Full Text] [Related]
9. Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy.
Pang XJ; Liu XJ; Liu Y; Liu WB; Li YR; Yu GX; Tian XY; Zhang YB; Song J; Jin CY; Zhang SY
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299525
[TBL] [Abstract][Full Text] [Related]
10. Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights.
Yoon H; Dehart JP; Murphy JM; Lim ST
J Histochem Cytochem; 2015 Feb; 63(2):114-28. PubMed ID: 25380750
[TBL] [Abstract][Full Text] [Related]
11. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
Behmoaram E; Bijian K; Jie S; Xu Y; Darnel A; Bismar TA; Alaoui-Jamali MA
Am J Pathol; 2008 Nov; 173(5):1540-50. PubMed ID: 18832579
[TBL] [Abstract][Full Text] [Related]
12. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
Shi Q; Hjelmeland AB; Keir ST; Song L; Wickman S; Jackson D; Ohmori O; Bigner DD; Friedman HS; Rich JN
Mol Carcinog; 2007 Jun; 46(6):488-96. PubMed ID: 17219439
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.
Schultze A; Fiedler W
Expert Opin Investig Drugs; 2010 Jun; 19(6):777-88. PubMed ID: 20465362
[TBL] [Abstract][Full Text] [Related]
14. FAK inhibitors in Cancer, a patent review.
Lv PC; Jiang AQ; Zhang WM; Zhu HL
Expert Opin Ther Pat; 2018 Feb; 28(2):139-145. PubMed ID: 29210300
[TBL] [Abstract][Full Text] [Related]
15. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
Lu Y; Sun H
J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
Stokes JB; Adair SJ; Slack-Davis JK; Walters DM; Tilghman RW; Hershey ED; Lowrey B; Thomas KS; Bouton AH; Hwang RF; Stelow EB; Parsons JT; Bauer TW
Mol Cancer Ther; 2011 Nov; 10(11):2135-45. PubMed ID: 21903606
[TBL] [Abstract][Full Text] [Related]
17. Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders.
Yang M; Xiang H; Luo G
Biochem Pharmacol; 2024 Jun; 224():116246. PubMed ID: 38685282
[TBL] [Abstract][Full Text] [Related]
18. Emerging roles of focal adhesion kinase in cancer.
Tai YL; Chen LC; Shen TL
Biomed Res Int; 2015; 2015():690690. PubMed ID: 25918719
[TBL] [Abstract][Full Text] [Related]
19. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma.
Crompton BD; Carlton AL; Thorner AR; Christie AL; Du J; Calicchio ML; Rivera MN; Fleming MD; Kohl NE; Kung AL; Stegmaier K
Cancer Res; 2013 May; 73(9):2873-83. PubMed ID: 23536552
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
